TY - JOUR
T1 - LUF7244, an allosteric modulator/activator of K
v11.1 channels, counteracts dofetilide-induced torsades de pointes arrhythmia in the chronic atrioventricular block dog model
AU - Qile, Muge
AU - Beekman, Henriette D M
AU - Sprenkeler, David J
AU - Houtman, Marien J C
AU - van Ham, W B
AU - Stary-Weinzinger, Anna
AU - Beyl, Stanislav
AU - Hering, Steffen
AU - van den Berg, Dirk-Jan
AU - de Lange, Elizabeth C M
AU - Heitman, Laura H
AU - IJzerman, Ad P
AU - Vos, Marc A
AU - van der Heyden, Marcel A G
N1 - Funding Information:
The research was funded by the Austrian Science Fund (FWF) Grant P27729 and the Chinese Scholarship Council. W.v.H. is supported by a travel grant from the Netherlands Heart Foundation (2018SB002). P. Oosterhoff, MatLab.
Funding Information:
The research was funded by the Austrian Science Fund (FWF) Grant P27729 and the Chinese Scholarship Council. W.v.H. is supported by a travel grant from the Netherlands Heart Foundation (2018SB002). P. Oosterhoff, MatLab.
Publisher Copyright:
© 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
PY - 2019/10
Y1 - 2019/10
N2 - Background and Purpose: K
v11.1 (hERG) channel blockade is an adverse effect of many drugs and lead compounds, associated with lethal cardiac arrhythmias. LUF7244 is a negative allosteric modulator/activator of K
v11.1 channels that inhibits early afterdepolarizations in vitro. We tested LUF7244 for antiarrhythmic efficacy and potential proarrhythmia in a dog model. Experimental Approach: LUF7244 was tested in vitro for (a) increasing human I
Kv11.1 and canine I
Kr and (b) decreasing dofetilide-induced action potential lengthening and early afterdepolarizations in cardiomyocytes derived from human induced pluripotent stem cells and canine isolated ventricular cardiomyocytes. In vivo, LUF7244 was given intravenously to anaesthetized dogs in sinus rhythm or with chronic atrioventricular block. Key Results: LUF7244 (0.5–10 μM) concentration dependently increased I
Kv11.1 by inhibiting inactivation. In vitro, LUF7244 (10 μM) had no effects on I
KIR2.1, I
Nav1.5, I
Ca-L, and I
Ks, doubled I
Kr, shortened human and canine action potential duration by approximately 50%, and inhibited dofetilide-induced early afterdepolarizations. LUF7244 (2.5 mg·kg
−1·15 min
−1) in dogs with sinus rhythm was not proarrhythmic and shortened, non-significantly, repolarization parameters (QTc: −6.8%). In dogs with chronic atrioventricular block, LUF7244 prevented dofetilide-induced torsades de pointes arrhythmias in 5/7 animals without normalization of the QTc. Peak LUF7244 plasma levels were 1.75 ± 0.80 during sinus rhythm and 2.34 ± 1.57 μM after chronic atrioventricular block. Conclusions and Implications: LUF7244 counteracted dofetilide-induced early afterdepolarizations in vitro and torsades de pointes in vivo. Allosteric modulators/activators of K
v11.1 channels might neutralize adverse cardiac effects of existing drugs and newly developed compounds that display QTc lengthening.
AB - Background and Purpose: K
v11.1 (hERG) channel blockade is an adverse effect of many drugs and lead compounds, associated with lethal cardiac arrhythmias. LUF7244 is a negative allosteric modulator/activator of K
v11.1 channels that inhibits early afterdepolarizations in vitro. We tested LUF7244 for antiarrhythmic efficacy and potential proarrhythmia in a dog model. Experimental Approach: LUF7244 was tested in vitro for (a) increasing human I
Kv11.1 and canine I
Kr and (b) decreasing dofetilide-induced action potential lengthening and early afterdepolarizations in cardiomyocytes derived from human induced pluripotent stem cells and canine isolated ventricular cardiomyocytes. In vivo, LUF7244 was given intravenously to anaesthetized dogs in sinus rhythm or with chronic atrioventricular block. Key Results: LUF7244 (0.5–10 μM) concentration dependently increased I
Kv11.1 by inhibiting inactivation. In vitro, LUF7244 (10 μM) had no effects on I
KIR2.1, I
Nav1.5, I
Ca-L, and I
Ks, doubled I
Kr, shortened human and canine action potential duration by approximately 50%, and inhibited dofetilide-induced early afterdepolarizations. LUF7244 (2.5 mg·kg
−1·15 min
−1) in dogs with sinus rhythm was not proarrhythmic and shortened, non-significantly, repolarization parameters (QTc: −6.8%). In dogs with chronic atrioventricular block, LUF7244 prevented dofetilide-induced torsades de pointes arrhythmias in 5/7 animals without normalization of the QTc. Peak LUF7244 plasma levels were 1.75 ± 0.80 during sinus rhythm and 2.34 ± 1.57 μM after chronic atrioventricular block. Conclusions and Implications: LUF7244 counteracted dofetilide-induced early afterdepolarizations in vitro and torsades de pointes in vivo. Allosteric modulators/activators of K
v11.1 channels might neutralize adverse cardiac effects of existing drugs and newly developed compounds that display QTc lengthening.
UR - http://www.scopus.com/inward/record.url?scp=85071363175&partnerID=8YFLogxK
U2 - 10.1111/bph.14798
DO - 10.1111/bph.14798
M3 - Article
C2 - 31339551
SN - 0007-1188
VL - 176
SP - 3871
EP - 3885
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 19
ER -